Filing Flows › 8-K events › Kiora Pharmaceuticals
Kiora Pharmaceuticals: entry into a material definitive agreement
Form 8-K filed Oct 29, 2026 · items 1.01, 7.01
Entry into a material definitive agreementKiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri
What the filing says
On October 23, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Senju Pharmaceutical Co., Ltd. (“Senju”) to license a late-stage neuroprotective, oral small-molecule calpain inhibitor (“KIO-401”). Under the Agreement, which has an effective date of Oct
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.